Myasthenia Gravis - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509240677

Publication Date:

September 13, 2024

Pages:

115

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Myasthenia gravis is a chronic autoimmune, neuromuscular disease that causes weakness in the skeletal muscles (the muscles that connect to your bones and contract to allow body movement in the arms and legs, and allow for breathing).
The global market for Myasthenia Gravis was estimated to be worth US$ 1185 million in 2023 and is forecast to a readjusted size of US$ 1955.9 million by 2030 with a CAGR of 6.4% during the forecast period 2024-2030
North American market for Myasthenia Gravis was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Myasthenia Gravis was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Myasthenia Gravis was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Myasthenia Gravis include Takeda, Roche, CSL Limited, Baxter International, Novartis, Bausch Health, Grifols, AstraZeneca and Avadel Pharmaceuticals, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Myasthenia Gravis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Myasthenia Gravis by region & country, by Type, and by Application.
The Myasthenia Gravis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myasthenia Gravis.
麻豆原创 Segmentation
By Company
Takeda
Roche
CSL Limited
Baxter International
Novartis
Bausch Health
Grifols
AstraZeneca
Avadel Pharmaceuticals
Octapharma
Astellas Pharma
Zydus Lifesciences
Kedrion S.p.A.
Segment by Type:
Monoclonal Antibodies
Intravenous Immunoglobulin
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Myasthenia Gravis manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Myasthenia Gravis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Myasthenia Gravis in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Myasthenia Gravis Product Introduction
1.2 Global Myasthenia Gravis 麻豆原创 Size Forecast
1.3 Myasthenia Gravis 麻豆原创 Trends & Drivers
1.3.1 Myasthenia Gravis Industry Trends
1.3.2 Myasthenia Gravis 麻豆原创 Drivers & Opportunity
1.3.3 Myasthenia Gravis 麻豆原创 Challenges
1.3.4 Myasthenia Gravis 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Myasthenia Gravis Players Revenue Ranking (2023)
2.2 Global Myasthenia Gravis Revenue by Company (2019-2024)
2.3 Key Companies Myasthenia Gravis Manufacturing Base Distribution and Headquarters
2.4 Key Companies Myasthenia Gravis Product Offered
2.5 Key Companies Time to Begin Mass Production of Myasthenia Gravis
2.6 Myasthenia Gravis 麻豆原创 Competitive Analysis
2.6.1 Myasthenia Gravis 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Myasthenia Gravis Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myasthenia Gravis as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Monoclonal Antibodies
3.1.2 Intravenous Immunoglobulin
3.1.3 Others
3.2 Global Myasthenia Gravis Sales Value by Type
3.2.1 Global Myasthenia Gravis Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Myasthenia Gravis Sales Value, by Type (2019-2030)
3.2.3 Global Myasthenia Gravis Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Online Pharmacies
4.2 Global Myasthenia Gravis Sales Value by Application
4.2.1 Global Myasthenia Gravis Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Myasthenia Gravis Sales Value, by Application (2019-2030)
4.2.3 Global Myasthenia Gravis Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Myasthenia Gravis Sales Value by Region
5.1.1 Global Myasthenia Gravis Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Myasthenia Gravis Sales Value by Region (2019-2024)
5.1.3 Global Myasthenia Gravis Sales Value by Region (2025-2030)
5.1.4 Global Myasthenia Gravis Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Myasthenia Gravis Sales Value, 2019-2030
5.2.2 North America Myasthenia Gravis Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Myasthenia Gravis Sales Value, 2019-2030
5.3.2 Europe Myasthenia Gravis Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Myasthenia Gravis Sales Value, 2019-2030
5.4.2 Asia Pacific Myasthenia Gravis Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Myasthenia Gravis Sales Value, 2019-2030
5.5.2 South America Myasthenia Gravis Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Myasthenia Gravis Sales Value, 2019-2030
5.6.2 Middle East & Africa Myasthenia Gravis Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Myasthenia Gravis Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Myasthenia Gravis Sales Value
6.3 United States
6.3.1 United States Myasthenia Gravis Sales Value, 2019-2030
6.3.2 United States Myasthenia Gravis Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Myasthenia Gravis Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Myasthenia Gravis Sales Value, 2019-2030
6.4.2 Europe Myasthenia Gravis Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Myasthenia Gravis Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Myasthenia Gravis Sales Value, 2019-2030
6.5.2 China Myasthenia Gravis Sales Value by Type (%), 2023 VS 2030
6.5.3 China Myasthenia Gravis Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Myasthenia Gravis Sales Value, 2019-2030
6.6.2 Japan Myasthenia Gravis Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Myasthenia Gravis Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Myasthenia Gravis Sales Value, 2019-2030
6.7.2 South Korea Myasthenia Gravis Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Myasthenia Gravis Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Myasthenia Gravis Sales Value, 2019-2030
6.8.2 Southeast Asia Myasthenia Gravis Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Myasthenia Gravis Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Myasthenia Gravis Sales Value, 2019-2030
6.9.2 India Myasthenia Gravis Sales Value by Type (%), 2023 VS 2030
6.9.3 India Myasthenia Gravis Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Takeda
7.1.1 Takeda Profile
7.1.2 Takeda Main Business
7.1.3 Takeda Myasthenia Gravis Products, Services and Solutions
7.1.4 Takeda Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.1.5 Takeda Recent Developments
7.2 Roche
7.2.1 Roche Profile
7.2.2 Roche Main Business
7.2.3 Roche Myasthenia Gravis Products, Services and Solutions
7.2.4 Roche Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.2.5 Roche Recent Developments
7.3 CSL Limited
7.3.1 CSL Limited Profile
7.3.2 CSL Limited Main Business
7.3.3 CSL Limited Myasthenia Gravis Products, Services and Solutions
7.3.4 CSL Limited Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.3.5 Baxter International Recent Developments
7.4 Baxter International
7.4.1 Baxter International Profile
7.4.2 Baxter International Main Business
7.4.3 Baxter International Myasthenia Gravis Products, Services and Solutions
7.4.4 Baxter International Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.4.5 Baxter International Recent Developments
7.5 Novartis
7.5.1 Novartis Profile
7.5.2 Novartis Main Business
7.5.3 Novartis Myasthenia Gravis Products, Services and Solutions
7.5.4 Novartis Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.5.5 Novartis Recent Developments
7.6 Bausch Health
7.6.1 Bausch Health Profile
7.6.2 Bausch Health Main Business
7.6.3 Bausch Health Myasthenia Gravis Products, Services and Solutions
7.6.4 Bausch Health Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.6.5 Bausch Health Recent Developments
7.7 Grifols
7.7.1 Grifols Profile
7.7.2 Grifols Main Business
7.7.3 Grifols Myasthenia Gravis Products, Services and Solutions
7.7.4 Grifols Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.7.5 Grifols Recent Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Profile
7.8.2 AstraZeneca Main Business
7.8.3 AstraZeneca Myasthenia Gravis Products, Services and Solutions
7.8.4 AstraZeneca Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.8.5 AstraZeneca Recent Developments
7.9 Avadel Pharmaceuticals
7.9.1 Avadel Pharmaceuticals Profile
7.9.2 Avadel Pharmaceuticals Main Business
7.9.3 Avadel Pharmaceuticals Myasthenia Gravis Products, Services and Solutions
7.9.4 Avadel Pharmaceuticals Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.9.5 Avadel Pharmaceuticals Recent Developments
7.10 Octapharma
7.10.1 Octapharma Profile
7.10.2 Octapharma Main Business
7.10.3 Octapharma Myasthenia Gravis Products, Services and Solutions
7.10.4 Octapharma Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.10.5 Octapharma Recent Developments
7.11 Astellas Pharma
7.11.1 Astellas Pharma Profile
7.11.2 Astellas Pharma Main Business
7.11.3 Astellas Pharma Myasthenia Gravis Products, Services and Solutions
7.11.4 Astellas Pharma Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.11.5 Astellas Pharma Recent Developments
7.12 Zydus Lifesciences
7.12.1 Zydus Lifesciences Profile
7.12.2 Zydus Lifesciences Main Business
7.12.3 Zydus Lifesciences Myasthenia Gravis Products, Services and Solutions
7.12.4 Zydus Lifesciences Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.12.5 Zydus Lifesciences Recent Developments
7.13 Kedrion S.p.A.
7.13.1 Kedrion S.p.A. Profile
7.13.2 Kedrion S.p.A. Main Business
7.13.3 Kedrion S.p.A. Myasthenia Gravis Products, Services and Solutions
7.13.4 Kedrion S.p.A. Myasthenia Gravis Revenue (US$ Million) & (2019-2024)
7.13.5 Kedrion S.p.A. Recent Developments
8 Industry Chain Analysis
8.1 Myasthenia Gravis Industrial Chain
8.2 Myasthenia Gravis Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Myasthenia Gravis Sales Model
8.5.2 Sales Channel
8.5.3 Myasthenia Gravis Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Takeda
Roche
CSL Limited
Baxter International
Novartis
Bausch Health
Grifols
AstraZeneca
Avadel Pharmaceuticals
Octapharma
Astellas Pharma
Zydus Lifesciences
Kedrion S.p.A.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.